A phase IIa study of prolonged use of cannabidiol in the prevention of Graft versus Host Disease

Trial Profile

A phase IIa study of prolonged use of cannabidiol in the prevention of Graft versus Host Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Sponsors TALENT Biotech
  • Most Recent Events

    • 16 Feb 2017 Results published in a Kalytera Therapeutics media release.
    • 03 Feb 2017 New trial record
    • 18 Jan 2017 Preliminary results published in a Kalytera Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top